A Phase 4 interventional study of Ribavirin in Hepatitis C, sponsored by Maastricht University Medical Center. Completed at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-01-09.
Sponsored by Maastricht University Medical Center · Phase 4, Interventional, and Treatment
The purpose of this study is to determine if the medicines for chronic hepatitis C can be taken once daily, instead of twice daily.
The standard treatment of patients with chronic hepatitis C infection (HCV) is treatment with ribavirin. Actually, the compliance (2x daily) seems to be a problem. To increase patients' compliance, it is investigated if the total dose of ribavirin can be taken once daily.
The pharmacokinetics of ribavirin at different dosage regimes is investigated.
2,321 studies on the registry are indexed under Hepatitis C; 102 are open to participants now.
This study's enrollment of 15 is below the median of 79 across 1,633 interventional studies indexed under Hepatitis C.
Browse Hepatitis C studies →Maastricht University Medical Center is the lead sponsor of 835 studies on the registry; 122 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: Ribavirin
Drug: Ribavirin
different dosing regimes of Ribavirin
The pharmacokinetics of ribavirin at different dosage regimes, measured by the area under the curve of the concentration-time graph
Time frame: within 24 weeks after enrollment
The tolerability of the treatment at different dosage regimes of ribavirin
Time frame: 24 weeks of treatment
The antioxidant capacity in plasma and erythrocytes at different dosing regimes
Time frame: 24 weeks of treatment
The effect of ribavirin on the hemolysis
Time frame: 24 weeks of treatment
The pharmacokinetics of ribavirin in erythrocytes in the different dosing regimes
Time frame: 24 weeks of treatment
This study is completed, as verified in Jul 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Maastricht University Medical Center